Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback